You have a patient with prediabetes in your exam room, and she asks a question you have heard more than once this year. "If these weight loss shots work so well, why am I still on metformin?" New research presented at the American Heart Association Scientific Sessions 2026 makes that question harder to brush off. In a large observational analysis, starting a GLP-1 drug rather than metformin was linked to better blood sugar outcomes and lower cardiovascular risk. So should GLP-1 for prediabetes be our default? The results are striking. The clinical decision is more complicated.
Researchers from Mayo Clinic presented the analysis at the AHA meeting in Chicago, held November 6 to 9. They pulled electronic health records from TriNetX across 104 institutions from 2010 to 2023 and matched 256,492 adults with prediabetes and obesity. The average age was 52 and 76% were women. Every patient started either metformin or a GLP-1 receptor agonist such as semaglutide, tirzepatide, liraglutide or dulaglutide, and outcomes were followed for about 3 years.
The differences were stark. Blood sugar returned to normal in 37.3% of the GLP-1 group compared with 29.3% of the metformin group. Progression to type 2 diabetes was 25.1% versus 37.0%, a 31% lower risk. The GLP-1 group was also 41% less likely to die from any cause and had less heart failure, ischemic stroke, heart attack and atrial fibrillation. Anyone who treats patients with obesity and prediabetes should pay attention to these results. They also need to be read carefully.
This was an observational study rather than a randomized trial. Matching patients on health record data makes the comparison fairer, but it can't remove every difference between people who received one drug and people who received the other. Unmeasured confounding is still possible. The team relied on diagnosis codes and had no data on adherence or dose. Because all GLP-1 drugs were analyzed together, we don't know whether semaglutide for prediabetes would match the pooled result. The abstract has not been peer reviewed, and the authors say randomized trials are needed.
What can we tell patients? That people on GLP-1 drugs did better in this analysis. We can't promise that starting one will reproduce those numbers. This is encouraging data that should shape our conversations. It is not a mandate to change practice.
Picture a familiar visit. A 50 year old woman with obesity and prediabetes has spent years trying to lose weight and keep it off. She read about this study, she is worried about developing diabetes like her mother, and she wants to switch from metformin to semaglutide.
This is where shared decision making pays off. The data suggest GLP-1 therapy could offer real benefits for patients who have both obesity and prediabetes. They don't show that every patient with prediabetes needs one. Metformin plus lifestyle change is still the standard first line approach. Her overall situation matters, and so do her goals, her ability to get the drug and her willingness to stay on it.
It also helps to separate two decisions that often get mixed up. Treating obesity in a patient who also has prediabetes is one question. Prescribing a drug specifically to prevent diabetes is another. They overlap but they are not the same. Patients deserve enthusiasm grounded in evidence, not promises the research can't yet back up.
The most intriguing question is how much of the benefit comes down to weight loss. These drugs cause weight loss, and in patients with obesity that alone may explain much of the change in glucose. The analysis can't tell us how much of the difference came from weight reduction and how much came from other drug effects or differences between the groups.
That distinction matters. If weight loss is the main driver, effective obesity treatment belongs at the center of every prediabetes treatment discussion. The cardiovascular and mortality results also need caution. Lower rates of heart failure, stroke, heart attack and atrial fibrillation are encouraging associations. They do not prove that the drugs prevented those events. Randomized trials will have to sort that out.
Now imagine a 38 year old man whose A1c just came back in the prediabetes range. He asks whether medication is the only real way to avoid diabetes. The answer is no.
Lifestyle intervention remains the mainstay of diabetes prevention. The CDC National Diabetes Prevention Program lifestyle change program cuts the risk of type 2 diabetes by about half. That is a big effect, and it shouldn't fall by the wayside because a newer class of drugs is in the spotlight. Metformin also remains a familiar, well understood choice alongside lifestyle change.
This is not about pills versus habits. It is about a plan the patient can stick to. For some that means structured help with nutrition, activity and weight. Others will need a medication discussion because of their weight and metabolic risk. A prescription should never replace the conversation about daily habits. And lifestyle advice should never become a reason to dismiss patients who have tried hard without reaching their goals.
Even when a patient understands the potential benefit, access often decides what happens next. GLP-1 drugs can be expensive. Coverage varies widely, and a prescription written for prediabetes alone may not be covered. A patient can be excited about the research and still be unable to get or afford the medication.
So talk about those barriers before you present GLP-1 therapy as a long term plan. Be honest about cost, about what happens if treatment stops and about the limits of the evidence we have today. Prediabetes deserves attention. It should not become another source of anxiety or a race to the newest prescription. Our job is to lay out reasonable options and help each patient pick one they can live with.
The Mayo Clinic analysis adds real weight to the conversation about GLP-1 for prediabetes. More patients returning to normal glucose, fewer progressing to diabetes and favorable cardiovascular signals are hard to ignore. Still, observational data can't settle which treatment should come first. Lifestyle change remains essential. Metformin still has a role. GLP-1 drugs may help selected patients, especially when obesity treatment is already on the table. What we need next is randomized evidence, head to head comparisons of individual drugs and practical answers on cost and access.
Are your patients asking about GLP-1 for prediabetes? How are you weighing this new evidence against metformin, lifestyle counseling and coverage barriers? Share your experience with fellow physicians in the MedSocially community.
Every doctor should take note of the results of Microsoft's diagnostic AI. In a study published in Science, the system outperformed generalist physicians on difficult diagnostic ca...
Physician burnout seems to be on the decline. It is good news for a profession that has felt exhausted and stressed for years. But another trend deserves attention. Clinics are ope...
Ambient AI nursing documentation is moving from concept to clinical use. For the last several years these tools were built around physician notes. Now they are moving into inpatien...
AI can write a convincing clinical explanation in seconds. Convincing does not always mean correct. As more of us bring clinical AI tools into daily practice, the question is no lo...
A patient needs treatment. You order it. The insurer demands more paperwork. Time goes by and the patient gives up. That is the quiet price of prior authorization delays, and new s...